Story

IREN Stock Slides as Competitor's IPO Filing Pressures AI Infrastructure Sector

ENTHMSVIIDZHZH-TWJAKOHI
Sep 25, 20261 min read
IREN Stock Slides as Competitor's IPO Filing Pressures AI Infrastructure Sector

Summary

Shares of IREN slid more than 5% amid a sector-wide selloff in AI cloud providers, sparked by a competitor's IPO filing that has raised investor concerns over valuations and pricing power.

Text size
Background

Shares of AI infrastructure provider IREN fell sharply in morning trading, caught in a sector-wide downdraft following the initial public offering filing from competitor Nscale last week. The pressure highlights growing investor scrutiny over valuations and long-term profitability in the burgeoning neocloud industry.

Market Reaction

IREN stock dropped 5.4% to $43.68 in morning trading, trading near the low end of its intraday range. The decline was not isolated, as other neocloud AI infrastructure companies also retreated.

The selling pressure appeared specific to the sector, as the broader S&P 500 and Nasdaq Composite indexes were trading nearly flat. This indicates that the selloff was driven by industry-specific concerns rather than macroeconomic factors.

Competitive Catalyst

The primary catalyst for the negative sentiment is the S-1 filing from Nscale, a UK-based AI cloud provider targeting a valuation of up to $35 billion. The high-profile filing has introduced fresh competitive benchmarks and intensified investor debate about supply dynamics and the sustainability of GPU pricing, a key revenue driver for the sector.

Sample IUX Markets – In-articleAd

This development followed a note from a Rothschild Redburn analyst earlier in the week, which initiated Sell ratings on IREN's peers CoreWeave and Nebius, citing concerns over the durability of GPU pricing. Bernstein analysts also weighed in, maintaining an Outperform rating on IREN but acknowledging that an easing of AI computing supply could eventually pressure the industry.

Valuation Overhang

The sector-wide concerns are compounding pressure on IREN, whose own financial performance remains a focus for investors. The company's fiscal year 2026 results showed a significant net loss of $702.6 million, which has created a persistent valuation overhang despite a 41.1% increase in revenue.

The combination of a new, formidable competitor, analyst caution on core pricing power, and IREN's unresolved profitability path has created a challenging backdrop for the stock.

Read next

More on Stocks
B. Riley Highlights Biotech Opportunities as Rate Hikes Pressure Sector

Stocks

B. Riley Highlights Biotech Opportunities as Rate Hikes Pressure Sector

Sep 25, 2026

An analyst at B. Riley has identified several biotech stocks poised for growth ahead of Q3 earnings, suggesting that recent market drawdowns driven by Federal Reserve rate hikes have created attractive entry points for investors. The firm points to strong company-specific catalysts and improving sector fundamentals despite the challenging macroeconomic environment.

Back to latest news

LATEST